AVEO to Identify Patient-Selection Biomarkers for OSI in $20M Cash and Equity Deal | GenomeWeb

NEW YORK (GenomeWeb News) - OSI Pharmaceuticals said today that it has expanded a translational research collaboration with AVEO Pharmaceuticals to develop patient-selection biomarkers for cancer therapies under development at OSI.

The partnership, originally announced in 2007, relates to the development of therapies to target epithelial-mesenchymal transition in cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.